AVITA Medical, Inc. (RCEL) News
Filter RCEL News Items
RCEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RCEL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RCEL News From Around the Web
Below are the latest news stories about AVITA MEDICAL INC that investors may wish to consider to help them evaluate RCEL as an investment opportunity.
AVITA Medical, Inc. (RCEL): A Bull Case TheoryWe came across a bullish thesis on AVITA Medical, Inc. (NASDAQ:RCEL) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RCEL. AVITA Medical, Inc. (NASDAQ:RCEL)’s share was trading at $8.94 as of Jan 8th. Avita Medical (NASDAQ:RCEL) has recently secured FDA approval for its new RECELL GO mini, a disposable cartridge […] |
AVITA Medical's shares sink 19% after another forecast cutAVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target. The U.S.-based company estimated its commercial revenue was about $64.3 million in fiscal 2024, lower than its forecast of $68 million to $70 million, due to slower-than-expected purchases from hospitals in the last quarter. AVITA's shares tumbled 18.8% to a two-month low of A$3.53, while the broader S&P/ASX 200 healthcare index was 0.7% higher. |
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial GuidanceVALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its fourth quarter and full-year 2024 commercial revenue guidance. For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4 million, reflecting growth of around 30% over the same period i |
Exploring High Growth Tech Stocks in the United States December 2024Over the last 7 days, the United States market has dropped 1.1%, yet it has risen by an impressive 22% over the past year, with earnings forecasted to grow by 15% annually. In this context of fluctuating short-term performance and promising long-term growth, identifying high growth tech stocks requires a focus on companies with strong innovation potential and robust financial health to capitalize on future opportunities. |
Cantor Fitzgerald bullish on Avita Medical after FDA approval for RECELL GO MiniCantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat smaller wounds that aren’t addressed by RECELL GO. Importantly, the firm expects that approval for Mini will allow the company to target smaller wounds within the company’s full thickness skin defect indication. Cantor notes Avita plans to roll out Mini across trauma and burn centers that treat smaller wound |
Avita Medical initiated with a Buy at D. Boral CapitalD. Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target Avita’s Recell technology has shown “promising results” in clinical trials for a variety of soft tissue and skin-related indications and Avita is “poised for significant growth” from expanding market penetration into trauma wounds, surgical wounds, and “slowly but surely chronic wounds” as awareness of the technology increases and adoption grows in hospitals and burn centers worldwide, the analyst |
FDA approves mini version of RECELL GO for smaller woundsAvita’s RECELL platform uses the regenerative properties of the patient’s own skin for wound treatment. |
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller WoundsRECELL GO mini AVITA Medical receives FDA approval of RECELL GO mini, a new addition to the RECELL Spray-On Skin™ technology platform. VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® min |
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable MarketNew collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDermCohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance fo |
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceVALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the presentation will be accessible under the Events & Presentat |